Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials

References

• Lascar N , Brown J , Pattison H , Barnett AH , Bailey CJ , Bellary S . Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol . 2018;6(1):69–80. doi:10.1016/S2213-8587(17)30186-9 28847479
   PubMed Web of Science ®Google Scholar
• Yang W , Lu J , Weng J , et al. Prevalence of diabetes among men and women in China. N Engl J Med . 2010;362(12):1090–1101. doi:10.1056/NEJMoa0908292 20335585
   PubMed Web of Science ®Google Scholar
• Worldwide trends in diabetes since. 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet . 2016;387(10027):1513–1530. doi:10.1016/S0140-6736(16)00618-8 27061677
   PubMed Web of Science ®Google Scholar
• Czech MP . Insulin action and resistance in obesity and type 2 diabetes. Nat Med . 2017;23(7):804–814. doi:10.1038/nm.4350 28697184
   PubMed Web of Science ®Google Scholar
• Valaiyapathi B , Gower B , Ashraf AP . Pathophysiology of type 2 diabetes in children and adolescents. Curr Diabetes Rev . 2018. doi:10.2174/1573399814666180608074510
   Web of Science ®Google Scholar
• Chamberlain JJ , Herman WH , Leal S , et al. Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med . 2017;166(8):572–578. doi:10.7326/M16-2937 28288484
   PubMed Web of Science ®Google Scholar
• Weng J , Ji L , Jia W , et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev . 2016;32(5):442–458. doi:10.1002/dmrr.2827 27464265
   PubMed Web of Science ®Google Scholar
• Raccah D , Huet D , Dib A , et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabet Med . 2017;34(9):1193–1204. doi:10.1111/dme.13390 28574177
   PubMed Web of Science ®Google Scholar
• Giugliano D , Sieradzki J , Stefanski A , Gentilella R . Personalized intensification of insulin therapy in type 2 diabetes – does a basal-bolus regimen suit all patients? Curr Med Res Opin . 2016;32(8):1425–1434. doi:10.1080/03007995.2016.1181051 27126277
   PubMed Web of Science ®Google Scholar
• Wang C , Mamza J , Idris I . Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med . 2015;32(5):585–594. doi:10.1111/dme.12694 25594251
   PubMed Web of Science ®Google Scholar
• Goh SY , Hussein Z , Rudijanto A . Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries. J Diabetes Investig . 2017;8(5):635–645. doi:10.1111/jdi.12647
   Web of Science ®Google Scholar
• Brown A , Guess N , Dornhorst A , Taheri S , Frost G . Insulin-associated weight gain in obese type 2 diabetes mellitus patients: what can be done? Diabetes Obes Metab . 2017;19(12):1655–1668. doi:10.1111/dom.13009 28509408
   PubMed Web of Science ®Google Scholar
• Stein SA , Lamos EM , Davis SN . A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf . 2013;12(2):153–175. doi:10.1517/14740338.2013.752813 23241069
   PubMed Web of Science ®Google Scholar
• Daniels MA , Kan C , Willmes DM , et al. Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. Pharmacogenomics J . 2016;16(5):399–410. doi:10.1038/tpj.2016.54 27432533
   PubMed Web of Science ®Google Scholar
• Del Prato S , Bianchi C , Marchetti P . beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev . 2007;23(7):518–527. doi:10.1002/dmrr.770 17883249
   PubMed Web of Science ®Google Scholar
• Waldrop G , Zhong J , Peters M , Rajagopalan S . Incretin-based therapy for diabetes: what a cardiologist needs to know. J Am Coll Cardiol . 2016;67(12):1488–1496. doi:10.1016/j.jacc.2015.12.058 27012410
   PubMed Web of Science ®Google Scholar
• Esposito K , Chiodini P , Maiorino MI , Bellastella G , Capuano A , Giugliano D . Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open . 2014;4(6):e005442. doi:10.1136/bmjopen-2014-005442
   PubMed Web of Science ®Google Scholar
• Drucker DJ , Nauck MA . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet . 2006;368(9548):1696–1705. doi:10.1016/S0140-6736(06)69705-5 17098089
   PubMed Web of Science ®Google Scholar
• Ling J , Cheng P , Ge L , et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol . 2019;56(3):249-272.
   Web of Science ®Google Scholar
• Ostergaard L , Frandsen CS , Madsbad S . Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Rev Clin Pharmacol . 2016;9(2):241–265. doi:10.1586/17512433.2016.1121808 26573176
   PubMed Web of Science ®Google Scholar
• Fonseca V , Schweizer A , Albrecht D , Baron MA , Chang I , Dejager S . Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia . 2007 50(6):1148–1155. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/414/CN-00609414/frame.html 17387446
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Rendell MS , Gross JL , Fleck PR , Wilson CA , Mekki Q . Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obesity Metab . 2009;11(12):1145–1152. doi:10.1111/dom.2009.11.issue-12
   PubMed Web of Science ®Google Scholar
• Vilsbøll T , Rosenstock J , Yki-Järvinen H , et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab . 2010;12(2):167–177. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/573/CN-00769573/frame.html 20092585
   PubMed Web of Science ®Google Scholar
• Barnett AH , Charbonnel B , Donovan M , Fleming D , Chen R . Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin . 2012 28(4):513–523. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/728/CN-00842728/frame.html 22313154
   PubMed Web of Science ®Google Scholar
• Hong ES , Khang AR , Yoon JW , et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab . 2012;14(9):795–802. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/500/CN-00842500/frame.html 22443183
   PubMed Web of Science ®Google Scholar
• Kadowaki T , Tajima N , Odawara M , et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int . 2013;4(3):160–172. doi:10.1007/s13340-013-0109-z
   Google Scholar
• Kothny W , Foley J , Kozlovski P , Shao Q , Gallwitz B , Lukashevich V . Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obesity Metab . 2013;15(3):252–257. doi:10.1111/dom.12020
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H , Rosenstock J , Durán-Garcia S , et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care . 2013;36(12):3875–3881. doi:10.2337/dc12-2718 24062327
   PubMed Web of Science ®Google Scholar
• Kaku K , Mori M , Kanoo T , Katou M , Seino Y . Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother . 2014 15(15):2121–2130. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/221/CN-01014221/frame.html 25190226
   PubMed Web of Science ®Google Scholar
• Hirose T , Suzuki M , Tsumiyama I . Efficacy and safety of vildagliptin as an add-on to insulin with or without metformin in japanese patients with type 2 diabetes mellitus: a 12-week, double-blind, randomized study. Diabetes Ther . 2015 6(4):559–571. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/281/CN-01125281/frame.html 26620049
   PubMed Web of Science ®Google Scholar
• Linjawi S , Sothiratnam R , Sari R , Andersen H , Hiort LC , Rao P . The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin - The Sit2Mix trial. Prim Care Diabetes . 2015 9(5):370–376. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/453/CN-01097453/frame.html 25488587
   PubMed Web of Science ®Google Scholar
• Mathieu C , Shankar RR , Lorber D , et al. A randomized clinical trial to evaluate the efficacy and safety of co-administration of sitagliptin with intensively titrated insulin glargine. Diabetes Ther . 2015;6(2):127–142. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/457/CN-01083457/frame.html 25820927
   PubMed Web of Science ®Google Scholar
• Otsuka Y , Yamaguchi S , Furukawa A , Kosuda M , Nakazaki M , Ishihara H . Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Endocr J . 2015 62(2):133–143. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/243/CN-01052243/frame.html 25328079
   PubMed Web of Science ®Google Scholar
• Sato S , Saisho Y , Kou K , et al. Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial. PLoS One . 2015;10(3):e0121988.25816296
   PubMed Web of Science ®Google Scholar
• Takahashi H , Sakai K , Kawanishi K , et al. Efficacy of switching from premix analog insulin twice daily injection to insulin glargine once daily injection with sitagliptin. Diabetol Int . 2015;6(1):33–38. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/123/CN-01069123/frame.html
   Google Scholar
• Mita T , Katakami N , Shiraiwa T , et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care . 2016;39(3):455–464. doi:10.2337/dc15-2145 26822324
   PubMed Web of Science ®Google Scholar
• Ning G , Wang WQ , Li L , et al. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J Diabetes . 2016;8(3):345–353. doi:10.1111/1753-0407.12303 25929739
   PubMed Web of Science ®Google Scholar
• Cao Y , Gao F , Zhang Q , et al. Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes. J Diabetes . 2017;9(5):502–509. doi:10.1111/1753-0407.12436 27255431
   PubMed Web of Science ®Google Scholar
• Kadowaki T , Kondo K , Sasaki N , et al. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother . 2017;18(13):1291–1300. doi:10.1080/14656566.2017.1359259 28741385
   PubMed Web of Science ®Google Scholar
• Kadowaki T , Muto S , Ouchi Y , Shimazaki R , Seino Y . Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opin Pharmacother . 2017;18(18):1903–1919. doi:10.1080/14656566.2017.1379990 28901796
   PubMed Web of Science ®Google Scholar
• Kanazawa I , Tanaka KI , Notsu M , et al. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment. Diabetes Res Clin Pract . 2017;123:9–17. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/601/CN-01301601/frame.html 27914297
   PubMed Web of Science ®Google Scholar
• Shankar RR , Bao YQ , Han P , et al. Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. J Diabetes Investig . 2017;8(3):321–329. doi:10.1111/jdi.12585
   Web of Science ®Google Scholar
• Chen C , Yu Q , Zhang S , Yang P , Wang CY . Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis. Int J Clin Exp Pathol . 2015;8(11):14141–14150.26823727
   PubMed Web of Science ®Google Scholar
• Kim YG , Min SH , Hahn S , Oh TJ , Park KS , Cho YM . Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract . 2016;116:86–95. doi:10.1016/j.diabres.2016.03.011 27321321
   PubMed Web of Science ®Google Scholar
• Moher D , Liberati A , Tetzlaff J , Altman DG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ . 2009;339:b2535. doi:10.1136/bmj.b2651 19622551
   PubMed Web of Science ®Google Scholar
• Higgins J , Green S . Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collab . 2011 Available from: www.cochranehandbook.org
   Google Scholar
• Higgins JP , Thompson SG , Deeks JJ , Altman DG . Measuring inconsistency in meta-analyses. BMJ . 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557 12958120
   PubMed Web of Science ®Google Scholar
• Egger M , Davey Smith G , Schneider M , Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ . 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629 9310563
   PubMed Web of Science ®Google Scholar
• Cho YM , Merchant CE , Kieffer TJ . Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther . 2012;135(3):247–278. doi:10.1016/j.pharmthera.2012.05.009 22659620
   PubMed Web of Science ®Google Scholar
• Yu M , Shankar RR , Zhang R , et al. Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. Diabetes Obes Metab . 2019;21(2):408–411. doi:10.1111/dom.13517 30178570
   PubMed Web of Science ®Google Scholar
• Min SH , Yoon JH , Hahn S , Cho YM . Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev . 2017;33(1):e2818. doi:10.1002/dmrr.v33.1
   Web of Science ®Google Scholar
• Yang W , Cai X , Gao X , Chen Y , Chen L , Ji L . Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: a meta-analysis. J Diabetes Investig . 2018;9(4):813–821. doi:10.1111/jdi.12764
   Web of Science ®Google Scholar